Real-world clinical study of trastuzumab biosimilar (Zercepac) and pertuzumab (Perjeta) in combination with chemotherapy for neoadjuvant treatment of HER-2-positive breast cancer.

Authors :: Bao YF
Yang JZ
Li XF
Zhu JJ
Source :: Asian journal of surgery [Asian J Surg] 2024 Jul; Vol. 47 (7), pp. 3225-3228. Date of Electronic Publication: 2024 Mar 23.
Publication Year :: 2024

Subjects :: Humans
Female
Middle Aged
Treatment Outcome
Adult
Aged
Antineoplastic Agents, Immunological administration & dosage
Antineoplastic Agents, Immunological therapeutic use
Breast Neoplasms drug therapy
Breast Neoplasms pathology
Trastuzumab administration & dosage
Trastuzumab therapeutic use
Antibodies, Monoclonal, Humanized administration & dosage
Antibodies, Monoclonal, Humanized therapeutic use
Neoadjuvant Therapy
Biosimilar Pharmaceuticals administration & dosage
Receptor, ErbB-2 metabolism
Antineoplastic Combined Chemotherapy Protocols therapeutic use

Full Text Access

Tools